IgG4-related disease. Clinical manifestation differential diagnosis and recent International Diagnostic Criteria for IgG4-related disease

1. Campr V. Monitor, aneb nemělo by vám uniknout, že co by hematopatolog měl vědět o IgG4-asociované nemoci. Česko‑slovenská patologie a Soudní lékařství. 2019;55-64 (4):200-2002.

2. Bojková M, Dítě P, Dvořáková J et al. Immunoglobulin G4, autoimmune pancreatitis and pancreatic cancer Digestive diseases (Basel. Online). 2015;33(1):86-90.

3. Hrnčíř Z. Nové imunoglobulinové biomarkery u revmatických chorob: volné lehké řetězce a IgG4. Rheumatologia (Bratislava). 2013;27(3):126-127.

4. Bartholomew LG, Cain JC, Woolner LB et al. Sclerosing cholangitis: its possible association with Riedel’s struma and fibrous retroperitonitis: report of two cases. N Engl J Med. 1963;269:8-12.

5. Yoshida K, Toki F, Takeuchi et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40:1561-1568.

6. Hamano H, Kawa S, Horiuchi A et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344(10):732-738.

7. Kamisawa T, Funata N, Hayashi Y et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003;38(10):982-984.

8. Hamano H, Kawa S, Ochi Y et al. Hydronephrosis associated with retroperitoneal fibrosis nand sclerosing pancreatitis. Lancet. 2002;359:1403-1404.

9. Dítě P. Husová L, Lukáš Z. Imunoglobulin G4 pozitivní cholangitida. Vnitř. Lék. 2010;56(8):824-826.

10. Dítě P, Novotný I, Kinkor Z. Autoimunní forma chronické pankreatitidy a IgG4 pozitivní mastitida Gastroenterologie a hepatologie. 2011;65(1):22-25.

11. Dítě P, Novotný I, Lata J et al. Autoimunitní pankreatitida a IgG pozitivní sklerotizující cholangitida. Vnitř. Lék. 2011;57(3):254-257.

12. Chari ST, Smyrk TC, Levy MJ et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol. 2006;4:1010-1016.

13. Ryu JK, Chung JB, Park SW et al. Review of 67 patients with autoimmune pancreatitis in Korea: a multicenter nationwide study. Pancreas. 2008;37:377-385.

14. Deshpande V, Zen Y, Chan JK et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181-1192.

15. Stone JH, Khosroshahi A, Deshpande V et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum. 2012;64(10):3061-3067.

16. Umehara H, Okazaki K, Masaki Y et al. Research Program for Intractable Disease by Ministry of Health, Labor and Welfare (MHLW) Japan G4 team. A novel clinical entity, IgG-4-related disease (IgG4RD): general concept and details. Mod Rheumatol. 2012;22(1):1-14.doi: 10.1007/s10165-011-0508-6.

17. Deshpande V. The pathology of IgG4-related disease: critical issues and challenges.Semin Diagn Pathol. 2012;29(4):191-196. doi:10.1053/j.semdp.2012. 08. 001.

18. Stone JH. IgG4-related disease: nomenclature, clinical features, and treatment. Semin Diagn Pathol. 2012;29(4):177-190. doi: 10.1053/j.semdp.2012. 08. 002.

19. Průcha M, Sedláčková L. IgG4-related disease - a patient with multiple organ involvement Prague Medical Report. 2017;118(2-3):95-99.

20. Uchida K, Masamune A, Shimosegawa T et al. Prevalence of IgG4-Related Disease in Japan Based on Nationwide Survey in 2009. Int J Rheumatol. 2012;2012:358-371.

21. Karim F, Loeffen J, Bramer W et al. IgG4-related disease: a systematic review of this unrecognized disease in pediatrics. Pediatr Rheumatol Online J. 2016;14(1):18.

22. Sasaki T, Akiyama M, Kaneko Y et al- IgG4-related disease and idiopathic multicentric Castleman’s disease: confusable immune‑mediated disorders. Rheumatology (Oxford). 2021 Aug 7:keab634. doi: 10.1093/rheumatology/keab634.

23. Mikulová Š, Jílek D, Richter J. Nemoc asociovaná s IgG4. Úvod, patogeneze, diagnostika. 1. část Alergie (Praha, Print). 2015;17(1):16-24.

24. Mikulová Š, Jílek D, Richter J. Nemoc asociovaná s IgG4. Klinický obraz, orgánová postižení a terapie. 2. část. Alergie (Praha, Print). 2015;17(2):91-99.

25. Král V, Pohorská J, Stiborová I et al. Onemocnění asociovaná s IgG4 – je příčinou porucha regulace imunitní odpovědi? Klinická imunológia a alergológia. 2016;26(1):42-48.

26. Endmayr V, Tunc C, Ergin L. Anti‑neuronal IgG4 autoimmune diseases and IgG4-related diseases may not be part of the same spectrum: a comparative study. Front Immunol. 2022;12:78547.

27. Koneczny I. Update on IgG4-mediated autoimmune diseases: New insights and new family members. Autoimmun Rev. 2020;19:102646.

28. Wallace ZS, Deshpande V, Mattoo H et al. IgG4-related disease: clinical and laboratory features in one hundred twenty‑five patients. Arthritis Rheumatol. 2015;67 (9):2466–2475.

29. Yamada K, Yamamoto M, Saeki T et al. New clues to the nature of immunoglobulin G4-related disease: a retrospective Japanese multicenter study of baseline clinical features of 334 cases. Arthritis Res Ther. 2017;19(1):262-270.

30. Hardacre JM, Iacobuzio‑Donahue CA et al. Results of pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis. Ann Surg. 2003;237:853–858.

31. Kunovský L, Dítě P, Blaho M et al. Is autoimmune pancreatitis a risk factor for pancreatic adenocarcinoma? Vnitř Lék. 2021;67(1), e9-e13.

32. Dítě P, Novotný I, Dvořáková J et al. Pancreatic Solid Focal Lesions: Differential Diagnosis between Autoimmune Pancreatitis and Pancreatic Cancer- Digestive diseases (Basel. Online). 2019;37(5):416-421.

33. Dítě P, Novotný I, Kianička B, et al. Autoimunitní pankreatitida – diagnostický konsenzus. Vnitř. Lék. 2015;61(2):114-118.

34. Peňázová P, Andrašina T, Novotný I et al. IgG4 sklerozující cholangitida – zánět imitující nádor hlavy pankreatu a cholangiokarcinom Klinická onkologie. 2019;32 (2):143-151.

35. Vaňásek J, Horrmann P, Laco J et al. IgG4 asociovaná pankreatitida a cholangoitida. Česká radiologie. 2014;68(4):294-297.

36. Takahashi M, Fujinaga Y, Notohara K et al. Working Group Members of The Research Program on Intractable Diseases from the Ministry of Labor, Welfare of Japan. Diagnostic imaging guide for autoimmune pancreatitis. Jpn J Radiol. 2020;38(7):591-612. doi: 10.1007/s11604-020-00971-z.

37. Notohara K, Kamisawa T, Fukushima N et al. Guidance for diagnosing autoimmune pancreatitis with biopsy tissues. Pathol Int. 2020;70(10):699-711. doi: 10.1111/pin.12994.

38. Novotný I, Dítě P, Trna J et al. Immunoglobulin G4-related cholangitis: a variant of IgG-4-related systemic disease. Digestive diseases (Basel. Online). 2012;30(2):216-219.

39. Dítě P, Novotný I, Kianička B et al. Imunologlobulin G4 associovaná onemocnění. Gastroenterológia pre prax. 2011;10(3):151-152.

40. Hubers LM, Beuers U. IgG4-related disease of the biliary tract and pancreas:clinical and experimental advances. Curr Opin Gastroenterol. 2017;33(4):310-314. doi: 10.1097/MOG.0000000000000362.

41. Dítě P, Trna J, Kinkor Z et al. Unusual Multiorgan Immunoglobulin G4 (IgG4) Inflammation: Autoimmune Pancreatitis, Mikulicz Syndrome, and IgG4 Mastitis. Gut and liver. 2013;7(5):621-624.

42. Honsová E, Loderová A, Kostolná E et al. Autoimunní pankreatitida s postižením žlučovodů a jater jako součást IgG4 pozitivního autoimunního onemocnění (IgG4-related autoimmune sclerosing disease). Kazuistika Česko‑slovenská patologie a Soudní lékařství. 2010;46-55(3):65-67.

43. Löhr JM, Beuers U, Vujasinovic M et al. UEG guideline working group.European Guideline on IgG4-related digestive disease - UEG and SGF evidence‑based recommendations. United European Gastroenterol J. 2020;8(6):637-666.doi: 10.1177/2050640620934911.

44. Kamisawa T, Nakazawa T, Tazuma S et al. Clinical practice guidelines for IgG4-related sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2019;26(1):9-42. doi: 10.1002/jhbp.596.

45. Chapman MH, Thorburn D, Hirschfield GM et al. British Society of Gastroenterology and UK‑PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68(8):1356-1378.doi: 10.1136/gutjnl-2018-317993.

46. Hori Y, Chari ST, Tsuji Y et al. Distinguishing IgG4-Related Sclerosing Cholangitis From Cholangiocarcinoma and Primary Sclerosing Cholangitis. Mayo Clin Proc Innov QualOutcomes. 2021;5(3):535-541. doi: 10.1016/j.mayocpiqo.2021. 03. 005.

47. Hrnčíř Z, Laco J. Klinický význam nemoci spojené s imunoglobuliny IgG4. Časopis lékařů českých. 2011;150(8):438-441.

48. Navarro‑Sánchez V, Marín‑Castañeda LA, Gallegos CA et al. IgG4-Related Fibrous Thyroiditis (Riedel’s Thyroiditis): A Case Report. Am J Case Rep. 2020;21:e928046. doi: 10.12659/AJCR.928046.

49. Rotondi M, Carbone A, Coperchini F et al. DIAGNOSIS OF ENDOCRINE DISEASE: IgG4-related thyroid autoimmune disease. Eur J Endocrinol. 2019;180(5):R175-R183. doi: 10.1530/EJE-18-1024.

50. Stan MN, Sonawane V, Sebo TJ et al. Riedel’s thyroiditis association with IgG4-related disease. Clin Endocrinol (Oxf). 2017;86(3):425-430. doi: 10.1111/cen.13238.

51. Takeshima K, Li Y, Kakudo K, et al. Proposal of diagnostic criteria for IgG4-related thyroid disease. Endocr J. 2021;68(1):1-6. doi: 10.1507/endocrj.EJ20-0557.

52. Laco J, Kamarádová K, Mottl R, et al. Plasma cell granuloma of the oral cavity: a mucosal manifestation of immunoglobulin G4-related disease or a mimic Virchows Archiv. 2015;466(3):255-63.

53. Kubíčková J, Zeleník K, Urban O et al. Manifestace IgG4 asociované nemoci v oblasti hlavy a krku. Otorinolaryngologie a foniatrie. 2015;64(3):163-167.

54. Hrnčíř Z, Laco J, Drahošová M et al. Biomarker IgG4 u Mikuliczovy choroby Rheumatologia (Bratislava). 2011;25(3)25-30.

55. Mačinga P, Jarošová J, Špičák J et al. Imonoglobulin G4 asociované onemocnění v gastroenterologii. Vnitř. Lék. 2021;67(2):76-83.

56. Laco J, Ryška A, Čelakovský P et al. Chronic sclerosing sialadenitis as one of the immunoglobulin G4-related diseases: a clinicopathological study of six cases from Central Europe. Histopathology (Oxford. Print). 2011;58(7):1157-1163.

57. Maehara T, Pillai S, Stone JH et al. Clinical features and mechanistic insights regarding IgG4-related dacryoadenitis and sialoadenitis: a review. Int J Oral Maxillofac Surg. 2019;48(7):908-916. doi: 10.1016/j.ijom.2019. 01. 006.

58. Marcus KS, Hoffman HT, Rajan Kd A et al. Not All Küttner Tumors Are IgG4-Related Disease (IgG4-RD). Head Neck Pathol. 2021. Jan 4. doi: 10.1007/s12105-020-01268-3.

59. Puxeddu I, Capecchi R, Carta F et al. Salivary Gland Pathology in IgG4-Related Disease: A Comprehensive Review. J Immunol Res. 2018;2018:6936727. doi: 10.1155/2018/6936727.

60. Liu Y, Xue M, Wang Z et al. Salivary gland involvement disparities in clinical characteristics of IgG4-related disease: a retrospective study of 428 patients. Rheumatology (Oxford). 2020;59(3):634-640. doi:10.1093/rheumatology/kez280.

61. Franeková L, Kozák I, Rovenský J. Onemocnění se vztahem k IgG4 Oftalmorevmatologie. První vydání. Praha, Galén 2017. 2017, 271-274.

62. Hrnčíř Z, Laco J, Slezák R et al. Mikuliczova choroba s jednostranným exoftalmem - onemocnění se vztahem k IgG4 Česká revmatologie. 2011;19(3):125-130.

63. Závorková M, Richter J, Větvička V, et al. IgG-4 asociované onemocnění v očním lékařství Česká a slovenská oftalmologie. 2017;73(3):109-112.

64. Detiger SE, Karim AF, Verdijk RM et al. The treatment outcomes in IgG4-related orbital disease: a systematic review of the literature. Acta Ophthalmol. 2019;97(5):451-459. doi: 10.1111/aos.14048.

65. Lee MJ, Planck SR, Choi D et al. Non‑specific orbital inflammation: Current understanding and unmet needs. Prog Retin Eye Res. 2021;81:100885. doi: 0.1016/j.preteyeres.2020.100885.

66. Lee HS, Choi W, Kim GE, Yoon KC. Case of Primary Isolated Subconjunctival IgG4-Related Disease. Cornea. 2018;37(7):926-928. doi:10.1097/ICO.0000000000001566.

67. Singh S, Selva D. Non‑infectious Dacryoadenitis. Surv Ophthalmol. 2021:S0039-6257(21)00135-1. doi: 10.1016/j.survophthal.2021. 05. 011.

68. Kubota T, Katayama M, Nishimura R et al. Long‑term outcomes of ocular adnexal lesions in IgG4-related ophthalmic disease. Br J Ophthalmol. 2020;104(3):345-349. doi: 10.1136/bjophthalmol-2018-313730.

69. Průcha M, Czinner P, Prokopová P et al. IgG4-related diseases - a rare polycystic form of Ormond’s disease. Prague Medical Report. 2016;117(2-3).124-128.

70. Průcha M, Sedláčková L. Onemocnění asociovaná s IgG4 – pacient s mnohočetným orgánovým postižením. Medicína po promoci. 2016;17(1):70-71.

71. Laco J, Podhola M, Kamarádová K et al. Idiopathic vs. secondary retroperitoneal fibrosis: a clinicopathological study of 12 cases, with emphasis to possible relationship to IgG-4-related disease. Virchows Archiv. 2013;463(5):721-30.

72. Průcha M, Kolombo I, Štádler P. Ormond’s Disease‑IgG4-related Disease. Prague Med Rep. 2015;116(3):181-92.

73. Průcha M, Šedivý P, Štádler P, et al. Aneurysma břišní aorty jako IgG4-asociované onemocnění? Anesteziologie a intenzivní medicína. 2017;28(1):53-54.

74. Bradna P, Soukup T, Tomáš J et al. Aortitis a periaortitis v rámci IgG4 – related choroby. Obtížná diagnóza s dobrou šancí léčby. Česká revmatologie. 2013;21(1):20-25.

75. Laco J, Šteiner I, Holuber T, et al., Isolated thoracic aortitis: clinicopathological and immunohistochemical study of 11 cases. Cardiovascular pathology. 2010;20(6):352-360.

76. Oyama‑Manabe N, Manabe O, Tsuneta S et al. RadioGraphics Update: IgG4-related Cardiovascular Disease from the Aorta to the Coronary Arteries. Radiographics. 2020;40(7):E29-E32. doi: 10.1148/rg.2020190219.

77. Mizushima I, Kasashima S, Fujinaga Y et al. Clinical and Pathological Characteristics of IgG4-Related Periaortitis/Periarteritis and Retroperitoneal Fibrosis Diagnosed Based on Experts‘ Diagnosis. Ann Vasc, DiS. 2019;12(4):460-472. doi: 10.3400/avd.oa.19-00085.

78. Šteiner I, Laco J, IgG4-related disease of the aortic valve. Cardiovascular pathology. 2015;24(4):264-265.

79. Lian L, Wang C, Tian JL. IgG4-related retroperitoneal fibrosis: a newly characterized disease. Int J Rheum, DiS. 2016;19(11):1049-1055. doi:10.1111/1756-185X.12863.

80. Liu Y, Zhu L, Wang Z, Zeng Q, et al. Clinical features of IgG4-related retroperitoneal fibrosis among 407 patients with IgG4-related disease: a retrospective study. Rheumatology (Oxford). 2021;60(2):767-772. doi: 10.1093/rheumatology/keaa411.

81. Wang G, Zhuo N, Luo X, et al. IgG4-Related Disease With Testicular involvement: A Case Report and Review of Literature. Front Immunol. 2021;12:717902. doi: 0.3389/fimmu. 2021.717902.

82. Crumley S, Ge Y, Zhou, et al. Interstitial cystitis: another IgG4-related inflammatory disease? Ann Diagn Pathol. 2013 Oct;17(5):403-7. doi: 10.1016/j.anndiagpath.2013. 03. 004.

83. Merta M. Klinický obraz onemocnění ledvin asociovaných s IgG4 Postgraduální nefrologie. 2013;11(2):26-27.

84. Tošovký M, Bradna P, Laco J et al. Case 1-2012: ANCA associated glomerulonephritis in combination with IgG4 Positive mediastinal mass in a patient with ankylosing spondylitis treated with TNF alpha inhibitors Acta Medica (Hradec Králové). 2012;55(1):42-46.

85. Kawano M, Saeki T, Nakashima H. IgG4-related kidney disease and retroperitoneal fibrosis: An update. Mod Rheumatol. 2019;29(2):231-239. doi:10.1080/14397595.2018.1554321

86. Boffa JJ, Esteve E, Buob D et al. Renal involvement in IgG4-related disease. Presse Med. 2020;49(1):104017. doi: 10.1016/j.lpm.2020.104017.

87. Kim YJ, Kim GE, Ma SK et al. IgG4-related renal disease co‑existing with retroperitoneal fibrosis. Transl Androl Urol. 2020;9(2):794-799. doi: 10.21037/tau.2020. 02. 06.

88. Tsai HC, Liao HT, Tsai CY. Retroperitoneal Fibrosis With a Damaged Kidney in IgG-4-Related Disease. J Clin Rheumatol. 2021;27(1):e1. doi:10.1097/RHU.0000000000001181.

89. Bhattad PB, Joseph DL, Peterson E. IgG4-Related Disease Manifesting as Hypocomplementemic Tubulointerstitial Nephritis: A Rare Case Report and Literature Review. J Investig Med High Impact Case Rep. 2020;8:2324709620952213. doi: 10.1177/2324709620952213.

90. Morales AT, Cignarella AG, Jabeen IS et al. An update on IgG4-related lung disease. Eur J Intern Med. 2019;66:18-24. doi:10.1016/j.ejim.2019. 06. 010.

91. Xie Y, Xiong A, Marion T et al. Lung nodules and IgG4 related disease: a single‑center based experience. BMC Pulm Med. 2020;20(1):218. doi: 10.1186/s12890-020-01250-3.

92. Moura MC, Gripaldo R, Baqir M et al. Thoracic Involvement in IgG4-Related Disease. Semin Respir Crit Care Med. 2020;41(2):202-213. doi: 10.1055/s-0039-1700995.

93. Lv X, Gao F, Liu Q et al. Clinical and pathological characteristics of IgG4-related interstitial lung disease. Exp Ther Med. 2018;15(2):1465-1473. doi: 10.3892/etm.2017.5554.

94. Matsui H, Utsumi T, Maru N, et al. A case of IgG4-related anterior mediastinal sclerosing disease coexisting with autoimmune pancreatitis. Surg Case Rep. 2020;6(1):180.doi: 10.1186/s40792-020-00939-1.

95. Corcoran JP, Culver EL, Anstey RM et al. Thoracic involvement in IgG4-related disease in a UK‑based patient cohort. Respir Med. 2017;132:117-121. doi: 10.1016/j.rmed.2017. 10. 005.

96. Pandita A, Wong J. IgG4-related disease in lung: a diagnostic challenge. Pathology. 2020;52(3):390-392. doi: 10.1016/j.pathol.2019. 11. 009.

97. Doubková M, Matěj R, Chovancová Z et al. Lung diseases and autoimmune hemolytic anemia associted with IgG4 disease. Vnitř Lék. 2020;66(4):47-52.

98. Terasaki Y, Ikushima S, Matsui S et al. Diffuse Lung Diseases Study Group. Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman’s disease. Histopathology. 2017;70(7):1114-1124. doi: 10.1111/his.13186.

99. Wick MR, O‘Malley DP. Lymphadenopathy associated with IgG4-related disease: Diagnosis & differential diagnosis. Semin Diagn Pathol. 2018;35(1):61-66. doi: 10.1053/j.semdp.2017. 11. 006.

100. Takanashi S, Kikuchi J, Sasaki T et al. Lymphadenopathy in IgG4-related disease: a phenotype of severe activity and poor prognosis, with eotaxin-3 as a new biomarker. Rheumatology (Oxford). 2021;60(2):967-975. doi: 10.1093/rheumatology/keaa648.

101. Bledsoe JR, Ferry JA, Neyaz A, et al. IgG4-related Lymphadenopathy: A Comparative Study of 41 Cases Reveals Distinctive Histopathologic Features. Am J Surg Pathol. 2021;45(2):178-192. doi: 10.1097/PAS.0000000000001579.

102. Igawa T, Hayashi T, Ishiguro K et al. IgG4-producing lymphoma arising in a patient with IgG4-related disease. Med Mol Morphol. 2016;49(4):243-249. doi: 10.1007/s00795-016-0139-2.

103. Wallace ZS, Carruthers MN, Khosroshahi A et al. IgG4-related disease and hypertrophic pachymeningitis. Medicine (Baltimore). 2013;92(4):206-216. doi:10.1097/MD.0b013e31829cce35.

104. Radotra BD, Aggarwal A, Kapoor A, et al. An orphan disease: IgG4-related spinal pachymeningitis: report of 2 cases. J Neurosurg Spine. 2016;25(6):790-794. doi: 10.3171/2016. 4. SPINE1674.

105. Sbeih I, Darwazeh R, Shehadeh M et al. Immunoglobulin G4-Related Hypertrophic Pachymeningitis of the Spine: A Case Report and Systematic Review of the Literature. World Neurosurg. 2020;143:445-453. doi: 10.1016/j.wneu.2020. 07. 227.

106. Pieringer H, Parzer I, Wöhrer A et al. IgG4-related disease: an orphan disease with many faces. Orphanet J Rare, DiS. 2014;9:110. doi: 10.1186/s13023-014-0110-z. PMID: 25026959;PMCID: PMC4223520.

107. Wallace ZS, Zhang Y, Perugino CA et al for ACR/EULAR IgG4-RD Classification Criteria Committee. Clinical phenotypes of IgG4-related disease: an analysis of two international cross‑sectional cohorts. Ann Rheum, DiS. 2019;78(3):406-412. doi: 10.1136/annrheumdis-2018-214603.

108. Luke YC Chen, Mattman A, Seidman MA et al. IgG4-related disease: what a hematologist needs to know Haematologica. 2019;104(3):444-455.

109. Della Torre E, Mattoo H, Mahajan VS et al. Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease. Allergy 2014;69(2):269-272.

110. Gotlib J. World Health Organization‑defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92(11):1243–1259.

111. Carruthers MN, Park S, Slack GW et al. IgG4-related disease and lymphocyte‑variant hypereosinophilic syndrome: A comparative case series. Eur J Haematol. 2017;98(4):378-387. doi:10.1111/ejh.12842.

112. Zhang X, Zhang P, Li J, et al. Different clinical patterns of IgG4-RD patients with and without eosinophilia. Sci Rep. 2019;9 (1):16483. doi: 10.1038/s41598-019-52847-6.

113. Dispenzieri A, Gertz MA, Therneau TM, Kyle RA. Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clin Proc. 2001;76(5):476-487.

114. Zhao EJ, Carruthers MN, Li CH, et al. Conditions associated with polyclonal hypergammaglobulinemia in the IgG4-related disease era: a retrospective study from a hematology tertiary care center. Haematologica. 2020;105(3):e121-e123. doi: 10.3324/haematol. 2019.219725.

115. Engelhart S, Glynn RJ, Schur PH. Disease associations with isolated elevations of each of the four IgG subclasses. Semin Arthritis Rheum. 2017;47(2):276-280.

116. Martín‑Nares E, Hernández‑Molina G, Baenas DF et al. IgG4-Related Disease: Mimickers and Diagnostic Pitfalls. J Clin Rheumatol. 2021 Sep 17. doi: 10.1097/RHU.0000000000001787. Epub ahead of print.

117. Soto Y, Kojima M, Takata K et al. Multicentric Castleman disease with abudant IgG4 positive cells. Clinical and pathological analysis of 6 cases. J Clin Pathol. 2010, 63, 1084-1089.

118. Otani K, Inoue D, Fujikura K, et al. Idiopathic multicentric Castleman’s disease: a clinicopathologic study in comparison with IgG4-related disease. Oncotarget. 2018;9(6):6691-6706.doi: 10.18632/oncotarget.24068.

119. Sun C, Xu G, Lin J. Comparison of IgG4-Related Lymphadenopathy and Multicentric Castleman’s Disease: a Retrospective Study. Clin Lab. 2018;64(10):1671-1678. doi: 10.7754/Clin. Lab. 2018.180421.

120. Sasaki T, Akiyama M, Kaneko Y et al. Distinct features distinguishing IgG4-related disease from multicentric Castleman’s disease. RMD Open. 2017;18;3(1):e000432. doi: 10.1136/rmdopen-2017-000432.

121. Zhang X, Zhang P, Peng L et al. Clinical characteristics of a concurrent condition of IgG4-RD and Castleman’s disease. Clin Rheumatol. 2018;37(12):3387-3395. doi: 10.1007/s10067-018-4165-4.

122. Gianella P, Dulguerov N, Arnoux G et al. Thyroid Rosai‑Dorfman disease with infiltration of IgG4-bearing plasma cells associated with multiple small pulmonary cysts. BMC Pulm Med. 2019;19(1):83. doi:10.1186/s12890-019-0847-1.

123. de Jong WK, Kluin PM, Groen HM. Overlapping immunoglobulin G4-related disease and Rosai‑Dorfman disease mimicking lung cancer. Eur Respir Rev. 2012;21(126):365-7. doi: 10.1183/09059180.00001612.

124. Zhang Y, Chen H, Jiang YQ et al. Clinicopathological features of cutaneous Rosai‑Dorfman disease and its relationship to IgG4-related disease: a retrospective study. Br J Dermatol. 2019;181(4):844-845. doi: 10.1111/bjd.17939.

125. Liu L, Perry AM, Cao W et al. Relationship between Rosai‑Dorfman disease and IgG4-related disease: study of 32 cases. Am J Clin Pathol. 2013;140(3):395-402. doi: 10.1309/AJCPFH0SJ6YILXJU.

126. Zhang X, Hyjek E, Vardiman J. A subset of Rosai‑Dorfman disease exhibits features of IgG4-related disease. Am J Clin Pathol. 2013;139(5):622-632.

127. Abla O, Jacobsen E, Picarsic J et al. Consensus recommendations for the diagnosis and clinical management of Rosai‑Dorfman‑Destombes disease. Blood. 2018;131(26):2877-2890.

128. Piao Y, Zhang Y, Yue C et al. Immunoglobulin G4-related chronic rhinosinusitis: a pitfall in the differential diagnosis of granulomatosis with polyangiitis, Rosai‑Dorfman disease, and fungal rhinosinusitis. Hum Pathol. 2018;73:82-88. doi: 10.1016/j.humpath.2017. 12. 011.

129. Bledsoe JR, Wallace ZS, Stone JH et al. Lymphomas in IgG4-related disease: clinicopathologic features in a Western population. Virchows Arch. 2017;472(5):839-852.

130. Liu J, Yin W, Westerberg LS, Lee P et al. Immune Dysregulation in IgG₄-Related Disease. Front Immunol. 2021;12:738540. doi: 10.3389/fimmu.2021.738540.

131. Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum, DiS. 2015;74(1):14-18.

132. Qi R, Chen LYC, Park S, et al. Utility of serum IgG4 levels in a multiethnic population. Am J Med Sci. 2018;355(1):61-66.

133. Dítě Z, Novotný I, Kala Z et al. Pozitivita imunoglobulinu IgG4 v krevním séru u osob s karcinomem slinivky břišní. Gastroenterologie a hepatologie. 2012;66(3):187-190.

134. Slavíčková J Lašťovička J. Elevace sérového imunoglobulinu G4 a diagnostika IgG4-asociované nemoci., Alergie (Praha, Print). 2018;20(2):98-102.

135. van der Gugten G, DeMarco ML, Chen LYC et al. Resolution of spurious immunonephelometric IgG subclass measurement discrepancies by LC‑MS/MS. Clin Chem. 2018;64(4):735-742.

136. Kawa S, Skold M, Ramsden DB, Serum IgG4 Concentration in IgG4-Related Disease. Clin Lab. 2017;63(9):1323-1337.

137. Wallace ZS, Mattoo H, Carruthers M et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum, DiS. 2015;74(1):190-195.

138. Mizushima I, Yamada K, Harada K et al. Diagnostic sensitivity of cutoff values of IgG4-positive plasma cell number and IgG4-positive/CD138-positive cell ratio in typical multiple lesions of patients with IgG4-related disease. Mod Rheumatol. 2018;28(2):293-299. doi: 10.1080/14397595.2017.1332540.

139. Akiyama M, Suzuki K, Yamaoka K et al. Number of Circulating Follicular Helper 2 T Cells Correlates With IgG4 and Interleukin-4 Levels and Plasmablast Numbers in IgG4-Related Disease. Arthritis R heumatol. 2015;67(9):2476-81.

140. Lanzillotta M, Della‑Torre E, Stone JH. Roles of Plasmablasts and B Cells in IgG4-Related Disease: Implications for Therapy and Early Treatment Outcomes. Curr Top Microbiol Immunol. 2017;401:85-92. doi: 10.1007/82_2016_58.

141. Lin W, Zhang P, Chen H, Lipsky PE. Circulating plasmablasts/plasma cells: a potential biomarker for IgG4-related disease. Arthritis Res Ther. 2017;19(1):25. doi: 10.1186/s13075-017-1231-2. PMID: 28183334;PMCID: PMC5301376.

142. Seidman MA, Barbour SJ, Levin A, Carruthers M, Chen LY. Recognizing IgG4-related tubulointerstitial nephritis. Can J Kidney Health, DiS. 2016;3:34.

143. Moriyama M, Ohta M, Furukawa S et al. The diagnostic utility of labial salivary gland biopsy in IgG4-related disease. Mod Rheumatol. 2016;26(5):725-729.

144. Umehara H, Okazaki K, Masaki Y et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD). Mod Rheumatol. 2012;22:21-30.

145. Umehara H, Okazaki K, Kawa S et al. Research Program for Intractable Disease by the Ministry of Health, Labor and Welfare (MHLW) Japan. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol. 2021;31(3):529-533. doi: 10.1080/14397595.2020.1859710,

146. Umehara H, Okazaki K, Nakamura T et al. Current approach to the diagnosis of IgG-4-related disease - Combination of comprehensive diagnostic and organ‑specific criteria. Mod Rheumatol. 2017;27(3):381-391.

147. Wallace ZS, Naden RP, Chari S et al for IgG4-RD Classification Criteria Working Group. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis 2020;79(1):77-87.

148. Wallace ZS, Naden RP, Chari S et al IgG4-Related Disease Classification Criteria Working Group. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. Arthritis Rheumatol. 2020;72(1):7-19.

149. Chovancová Z, Filipenský P, Rotnáglová S et al. Podtřída imunoglobulinů IgG4 a s ní související patologické stavy aneb jak účinně imitovat nádorové onemocnění Klinická onkologie. 2022;35(1):20-31.

150. Wallace ZS, Khosroshahi A, Carruthers MD et al. An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index. Arthritis Care Res (Hoboken). 2018;70(11):1671-1678. doi: 10.1002/acr.23543.

151. Fernández‑Codina A, Pinilla B et al. Spanish Registry of IgG4 Related Disease (REERIGG4) investigators;Autoimmune Diseases Group (GEAS);Spanish Internal Medicine Society (SEMI). Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index. Joint Bone Spine. 2018;85(6):721-726. doi: 10.1016/j.jbspin.2018. 01. 014.

152. Zhang X, Zhang P, Li J et al. Different clinical patterns of IgG4-RD patients with and without eosinophilia. Sci Rep. 2019;9(1):16483. doi: 10.1038/s41598-019-52847-6.

153. Tomiyama F, Watanabe R, Fujii H et al. Synovitis in a Patient with IgG4-related Disease. Intern Med. 2015;54(11):1427-32. doi: 0.2169/internalmedicine.54.4320.